Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial

To evaluate the effect of this plant as adjunctive therapy on Helicobacter pylori (H. pylori) eradication.

The plant capsules were prepared and their physicochemical properties were assessed. In this clinical trial, 99 patients with H. pylori infection were randomized to receive Salvia mirzayanii Rech. f. & Esfand (S. mirzayanii) or placebo capsules for two weeks. All the patients in both groups received clarithromycin-based triple therapy. Both intention to treat and per protocol analyses were performed. Eradication rates, treatment side effects, and medication compliance were evaluated in both groups.

H. pylori eradication rate of all the randomized participants was 59.59%. The eradication rate of H. pyloriwas significantly higher in S. mirzayanii group compared with that in the placebo group for per protocol analysis (84.62%, P = 0.026) but not for intention to treat one (65.31%, P = 0.252). There were no significant differences between the two groups regarding the frequencies of the medications side effects and the patients with poor compliance.

The use of S. mirzayanii as adjunctive therapy to 14-day clarithromycin-based triple therapy might improve H. pylorieradication rate.